|
|
|
|
 Dr Jens Oliver Funk,
Senior Vice President R&D, Global Head Therapeutic Area Oncology Merck Serono Jens Oliver Funk, MD, Senior Vice President, is Global Head of the Therapeutic Area Oncology in Merck Serono R&D. He is responsible for the Oncology discovery portfolio. The operational responsibility includes discovery and translational research as well as biomarker discovery for all Oncology R&D projects. Together with his global team in Boston and Darmstadt he has brought more than ten new biologics and small molecules into clinical development. He is also part of the leadership team that steers the proof-of-concept and development strategy for the clinical portfolio. Dr.
Funk held various senior positions within Oncology – Preclinical R&D at Merck KGaA, before taking responsibility for the TA Oncology within Merck Serono at the beginning of 2007.
Jens Oliver Funk studied Medicine in Lübeck, Edinburgh, and Stanford, and holds a Board Certification and Professorship in Clinical and Molecular Dermatology. His focus has been on basic and translational cancer research in several fields. Prior to joining Merck KGaA in 2002, Dr. Funk worked in various research and clinical positions at reknown cancer research centers in Munich, Erlangen, San Francisco, and Seattle. Appearing: DAY 3 THURSDAY 23 SEPTEMBER – CLINICAL TRIALS, COLLABORATIONS & COMBINATION THERAPY 9.40am Putting diagnostics into practice for effective clinical trials: what is the impact of patient stratification and narrowing the market?
- Considering the genetic heterogeneity of cancer and subsequent options for targeting the disease.
- Is the trade-off between targeting a narrower market and improved efficacy a realistic worthwhile investment?
- What steps are being taken to better tailor particular therapies to particular patients?
Dr Jens Oliver Funk, Senior Vice President R&D, Global Head Therapeutic Area Oncology,
Merck Serono 3.30pm Extended panel discussion with Q&A: how is big pharma driving targeted cancer therapies to the forefront of the oncology industry?
- Scientifically – what are the areas of greatest potential for further development? Which industry profiles hold the key to developing them?
- Clinically – has the time come to readdress how oncology trials are planned and executed? What are the alternatives?
- Commercially – how can we integrate science and clinical outcomes into a successful business plan that meets the requirements of drug developers, patients, clinicians and government?
Vice President Oncology R&D,
Biogen Idec Dr Jens Oliver Funk, Senior Vice President R&D, Global Head Therapeutic Area Oncology,
Merck Serono Vice President Clinical Oncology,
Human Genome Sciences Global Brand Physician,
AstraZeneca Pharmaceuticals |
|
|
|
|
Conference:
Day 1
September 21, 8:30am - 5:30pm
Day 2
September 22, 8:30am - 5:30pm
Day 3
September 23, 9am - 5:30pm
|
|
|
|
|
|
|
|
|
